First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation

Cohen Adam D.; Popat Rakesh; Trudel Suzanne; Richardson Paul G.; Libby Ed N. III; Lendvai Nikoletta; Anderson Larry D. Jr.; Sutherland Heather J.; DeWall Stephen; Ellis Catherine E.; He Zangdong; Mazumdar Jolly; Wang Catherine; Opalinska Joanna B.; Voorhees Peter M.

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation

【24h】

First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation

机译：首先在与GSK2857916进行的人类研究中，将与微管破坏剂缀合的抗体药物，其针对复发/难治多骨髓瘤（MM）的患者中针对B细胞成熟抗原（BCMA）的抗原（BCMA）：研究BMA117159部分1剂量升级

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2016年第22期|共5页
作者
Cohen Adam D.; Popat Rakesh; Trudel Suzanne; Richardson Paul G.; Libby Ed N. III; Lendvai Nikoletta; Anderson Larry D. Jr.; Sutherland Heather J.; DeWall Stephen; Ellis Catherine E.; He Zangdong; Mazumdar Jolly; Wang Catherine; Opalinska Joanna B.; Voorhees Peter M.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation [J] . Cohen Adam D., Popat Rakesh, Trudel Suzanne, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：首先在与GSK2857916进行的人类研究中，将与微管破坏剂缀合的抗体药物，其针对复发/难治多骨髓瘤（MM）的患者中针对B细胞成熟抗原（BCMA）的抗原（BCMA）：研究BMA117159部分1剂量升级
2. Expression of Myeloma Cell and Soluble B-Cell Maturation Antigen (BCMA) in Relapsed and Refractory Multiple Myeloma Patients Treated with GSK2857916 in BMA117159 [J] . Dettman E. J., Rigat Fabio, Albert Josh, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：骨髓瘤细胞和可溶性B细胞成熟抗原（BCMA）在BMA117159中GSK2857916治疗的复发和难治性多发性骨髓瘤患者中的表达
3. Treatment with AMG 420, an Anti-B-Cell Maturation Antigen (BCMA) Bispecific T-Cell Engager (BiTE (R)) Antibody Construct, Induces Minimal Residual Disease (MRD) Negative Complete Responses in Relapsed and/or Refractory (R/R) Multiple Myeloma (MM) Patients: Results of a First-in-Human (FIH) Phase I Dose Escalation Study [J] . Topp Max S., Duell Johannes, Zugmaier Gerhard, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：用AMG 420处理，一种抗B细胞成熟抗原（BCMA）双特异性T细胞参录手（咬合（R））抗体构建体，诱导最小的残留疾病（MRD）在复发和/或难治度（R / R））多发性骨髓瘤（mm）患者：先进（FIH）I剂量升级研究的结果
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Antibody–drug conjugate GSK2857916 in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study [O] . Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, 2019

机译：抗体/药物偶联物GSK2857916在复发/难治性多发性骨髓瘤中的应用：剂量扩展I期研究的安全性和有效性更新
6. Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study [O] . Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, 2019

机译：抗体 - 药物缀合物，GSK2857916，复发/难治性多发性骨髓瘤：我研究的剂量扩张阶段的安全性和疗效的更新

First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation

著录项

相似文献

相关主题

期刊订阅